

Prepared on 18/10/2019

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of this investment product and complements the Prospectus¹
- It is important to read the Prospectus before deciding whether to purchase the product. If you do not have a copy, please contact us to ask for one.
- You should not invest in the product if you do not understand it or are not comfortable with the accompanying risks.
- If you wish to purchase the product, you will need to make an application in the manner set out in the Prospectus.

Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund (the "Fund")

Product Type	Investment Company	Launch Date	03/04/2000	
Investment Manager	Franklin Advisers, Inc.	Custodian	J.P. Morgan Bank Luxembourg S.A.	
Management Company	Franklin Templeton International Services S.à r.l.			
Trustee	Nil	Dealing Frequency	Daily (Dealing Days only)	
Capital Guaranteed	No	Expense Ratio for Financial Year Ended 30/06/2019	Share Class	Range
			A	1.82%
			B~	3.13%
			C	2.40%
			I	0.97%
			N	2.57%
			W	1.02%
			Z	1.31-1.33%
PRODUCT SUITABILITY				
WHO IS THE PRODUCT SUITABLE FOR? The Fund is <u>only</u> suitable for investors who: <ul style="list-style-type: none">• seek capital appreciation;• seek a growth investment in equity securities in the biotechnology sector in the US and around the world; and• plan to hold their investment for the medium to long term. The principal may be at risk.			Further Information Refer to “Fund Information, Objectives and Investment Policies” of the Luxembourg Prospectus.	
KEY PRODUCT FEATURES				
WHAT ARE YOU INVESTING IN? <ul style="list-style-type: none">• You are investing in an open-ended collective investment scheme (constituted in Luxembourg as a UCITS that aims to provide you with capital appreciation by a growth investment in equity securities in the biotechnology sector in the US and around the world.			Refer to “Investment Objective, Focus and Approach of the Funds” section of the Singapore Prospectus, and the “Dividend Policy” section of the Luxembourg Prospectus.	
Investment Strategy				

¹ The Prospectus is available for collection from Templeton Asset Management Ltd at 7 Temasek Boulevard , # 38-03 Suntec Tower One , Singapore 038987 and its appointed distributors during business hours , or accessible at www.franklintempleton.com.sg

~Class B Shares will no longer be available for subscription with effect from 1 April 2016

<ul style="list-style-type: none"> • The Fund will invest principally in equity securities of biotechnology companies and discovery research firms of any size located in the US and other countries. • It may also invest in debt securities of any type of issuers worldwide. • A biotechnology company is one that has at least 50% of its earnings coming from, or at least 50% of its net assets devoted to, biotechnology activities. The Fund will usually invest more in the US than in any other individual country although it may have more than 50% of its net assets in non-US securities. • The Fund may invest in derivatives for the purposes of hedging and/or efficient portfolio management. 	Refer to “Investment Objective, Focus and Approach of Funds” section of the Singapore Prospectus.
Parties Involved	
WHO YOU ARE INVESTING WITH? <ul style="list-style-type: none"> • The investment company is Franklin Templeton Investment Funds. • The investment manager is Franklin Advisers, Inc. • The management company is Franklin Templeton International Services S.à r.l. • The custodian is J.P. Morgan Bank Luxembourg S.A. • The Singapore representative is Templeton Asset Management Ltd. 	Refer to “Management and Administration” section of the Singapore Prospectus for more information on the role and responsibilities of these entities and what happens if they become insolvent.
KEY RISKS	
WHAT ARE THE KEY RISKS OF THIS INVESTMENT? The value of the product and its dividends or coupons may rise or fall. These risk factors may cause you to lose some or all of your investment.	Refer to the “Risk Factors” section of the Singapore Prospectus and “Risk Considerations” section of the Luxembourg Prospectus.
Market and Credit Risks	
<ul style="list-style-type: none"> • Your investments are exposed to equity markets risk. Your investments may be subject to significant price movements due to the impact of economic, political, market, and issuer-specific factors. 	
Liquidity Risks	
Your investments are exposed to liquidity risks of the underlying investments. <ul style="list-style-type: none"> • Under exceptional market conditions the manager may be forced to sell assets of the fund at a discount in order to meet continued redemption requests. The Fund is not listed, and you can realize your units only on Dealing Days. <ul style="list-style-type: none"> • There is no secondary market for the Fund. All redemption requests should be submitted in the manner set out in the Prospectus. Your realization request may be deferred or suspended. <ul style="list-style-type: none"> • Redemptions of Shares may be deferred when more than 10% of the value of the Fund’s Shares are redeemed or exchanged on any one Dealing Day. Your right to realize units may also be temporarily suspended under certain circumstances as described in the Prospectus. 	Refer to the sections “Sale of Shares” and “Suspension of Valuation, Issue, Sale and Switching of Shares” of the Singapore Prospectus.
Product-Specific Risks	
You are exposed to risk associated with the biotechnology sectors. <ul style="list-style-type: none"> • The Fund tends to invest in the biotechnology sectors. These sectors may present greater risk and higher volatility than investment in a broader range of securities covering different economic sectors and tend to be subject to greater government regulation, which could have an adverse impact on the Fund’s performance. 	

	Management Fee	& Servicing Charges ³													
Share Class A	1.00%	Maintenance: Up to 0.50%	<ul style="list-style-type: none">• Annual Custodian Fee: 0.01% to 0.14% p.a.• Annual Admin Fee: Max. 0.20% p.a. plus additional amount per Investor Holding over one-year period• Annual Investment Management Fee retained by management company = 52.5% to 100%• Annual Investment Management Fee paid by management company to financial adviser or distributor (trailer fee)* = 0% to 47.5%												
Share Class B~	1.00%	Maintenance: Up to 0.75% Servicing: Up to 1.06%													
Share Class C	1.00%	Maintenance: Up to 1.08% Servicing: Up to 1.08%													
Share Class I	0.70%	Nil													
Share Class N	1.00%	Maintenance: 1.25%													
Share Class W	0.75%	Nil													
Share Class Z	1.00%	Nil													
VALUATIONS AND EXITING FROM THIS INVESTMENT															
HOW OFTEN ARE VALUATIONS AVAILABLE? <ul style="list-style-type: none">• Daily valuations are available on Dealing Days.• The indicative NAV and actual NAV per share of each Fund and Share Class may be obtained from the Singapore representative and will be published on the Singapore representative’s website (www.franklintempleton.com.sg) one Singapore Business Day after the relevant Dealing Day. HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO? <ul style="list-style-type: none">• To exit the Fund you should complete the relevant sale form, together with such other documents as may be required and submit it to the Singapore representative or through the financial advisor or distributor from whom you purchased the Fund, the Internet or any other sales channels, if applicable.• Please note that sale of Class B and C shares may be subject to exit charges.• Some appointed distributors may offer a cancellation policy whereby you will not incur the sales charges if you sell during the relevant period (the Fund does not offer such cancellation policy). You will however take the risk of a decline in the Fund’s NAV since you purchased it and certain administrative fees may apply.• Sale proceeds will be paid within three Singapore Business Days following the Dealing Day of the receipt and acceptance of the sale request. Sale proceeds from investments using SRS monies will be returned to your SRS account.• Your exit price is determined as follows:<ul style="list-style-type: none">- If the Singapore representative receives and accepts the sale request on or before 4 p.m. on a Dealing Day, you will be paid a price based on the net asset value of the Shares applicable on that day.- If the Singapore representative receives and accepts the sale request after 4 p.m. on a Dealing Day, you will be paid a price based on the net asset value of the Shares at the close of the next Dealing Day.• The following illustrates the sales proceeds on a sale of 1,000 Class A SGD share class shares at an exit price of S\$12.50 and assuming no Contingent Deferred Sales Charge:<table><tr><td>Exit price x Number of shares sold</td><td>=</td><td>Gross Sales Proceeds</td></tr><tr><td>S\$12.50 x 1,000</td><td>=</td><td>S\$12,500</td></tr><tr><td>Gross Sales Proceeds – Exit Charges</td><td>=</td><td>Net Sales Proceeds</td></tr><tr><td>S\$12,500-S\$0.00</td><td>=</td><td>S\$12,500</td></tr></table>			Exit price x Number of shares sold	=	Gross Sales Proceeds	S\$12.50 x 1,000	=	S\$12,500	Gross Sales Proceeds – Exit Charges	=	Net Sales Proceeds	S\$12,500-S\$0.00	=	S\$12,500	Refer to the “Purchase of Shares”, “Sale of Shares” and “Obtaining Price Information” sections of the Singapore Prospectus.
Exit price x Number of shares sold	=	Gross Sales Proceeds													
S\$12.50 x 1,000	=	S\$12,500													
Gross Sales Proceeds – Exit Charges	=	Net Sales Proceeds													
S\$12,500-S\$0.00	=	S\$12,500													
CONTACT INFORMATION															

³ Payable to principal distributor, based on the applicable average net asset value.

HOW DO YOU CONTACT US?

- For account-related matters and product information, kindly contact the financial advisor or distributor from whom you purchased the Fund.
- For product-related queries, kindly contact Templeton Asset Management Ltd at 7 Temasek Boulevard, #38-03 Suntec Tower One, Singapore 038987(Address), +65 6241 2662 (tel.), www.franklintempleton.com.sg (website). Client Dealer Services Representative is available at +65 6337 3933 (tel.), cdsspr@franklintempleton.com (email)

GLOSSARY

“**Dealing Day**” means each day which is both a Valuation Day and a Singapore Business Day, or otherwise as the Directors may from time to time determine.

“**NAV**” means Net Asset Value.

“**Singapore Business Day**” means a day (except Saturdays, Sundays and public holidays) on which commercial banks are open for business in Singapore.

“**UCITS**” means an undertaking for collective investment in transfer securities.

“**Valuation Day**” means any day on which the New York Stock Exchange (NYSE) is open or any full day on which banks in Luxembourg are open for normal business (other than during a suspension of normal dealing).